Clinical trial
Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately…
NCT00104403 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00104403 |
|---|---|
| Title | Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy |
| Official title | A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Study of the Safety and Efficacy of the Oral NeuroKinin-1 Receptor Antagonist, GW679769 in Combination With Ondansetron Hydrochloride and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Nausea and Vomiting, Chemotherapy-Induced, Chemotherapy-Induced Nausea and Vomiting |
| Intervention type | Drug |
| Interventions | GW679769, Dexamethasone, Ondansetron Hydrochloride |
| Enrollment | 722 |
| Start date | Dec 1, 2004 |
| Primary completion | Jan 1, 2006 |
| Completion | Jan 1, 2006 |
| First posted | Mar 1, 2005 |
| Last update posted | Apr 16, 2015 |
| Countries | Argentina, Austria, Canada, Chile, Croatia, Czechia, Germany, Greece, Hong Kong, Hungary, Ireland, Mexico and 12 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: